Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,037

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

April 30, 2018

Study Completion Date

October 31, 2018

Conditions
Post-ERCP Pancreatitis
Interventions
DRUG

high dose indomethacin

patients randomized to this intervention receive 200mg indomethacin

DRUG

standard dose indomethacin

patients randomized to this intervention receive 100mg indomethacin

Trial Locations (6)

29425

Medical University of South Carolina, Charleston

46202

Indiana University Health, Indianapolis

48109

University of Michigan Medical Center, Ann Arbor

53220

Aurora St. Lukes' Medical Center, Milwaukee

75203

Methodist Dallas Medical Center, Dallas

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

American College of Gastroenterology

OTHER

collaborator

University of Michigan

OTHER

collaborator

University of Texas

OTHER

collaborator

Wake Forest University Health Sciences

OTHER

collaborator

Medical University of South Carolina

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Indiana University

OTHER

NCT01912716 - Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis | Biotech Hunter | Biotech Hunter